EP1985302A4 - Arzneimittel zur tumortherapie und seine verwendung - Google Patents

Arzneimittel zur tumortherapie und seine verwendung

Info

Publication number: EP1985302A4
Authority: EP; European Patent Office
Prior art keywords: tumors; medicament; treatment
Prior art date: 2006-01-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP07702136A

Other languages

English (en)

French (fr)

Other versions

EP1985302B1 (de

EP1985302A1 (de

Inventor

Yongzhang Luo

Qing Han

Qingxin Lei

Guodong Chang

Yan Fu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tsinghua University

Protgen Ltd

Original Assignee

Tsinghua University

Protgen Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-20

Filing date

2007-01-19

Publication date

2013-01-02

2007-01-19 Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University

2008-10-29 Publication of EP1985302A1 publication Critical patent/EP1985302A1/de

2013-01-02 Publication of EP1985302A4 publication Critical patent/EP1985302A4/de

2018-01-03 Application granted granted Critical

2018-01-03 Publication of EP1985302B1 publication Critical patent/EP1985302B1/de

Status Active legal-status Critical Current

2027-01-19 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP07702136.8A 2006-01-20 2007-01-19 Arzneimittel zur tumortherapie und seine verwendung Active EP1985302B1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CNB2006100112479A CN100475270C (zh)	2006-01-20	2006-01-20	一种治疗肿瘤的药物及其应用
PCT/CN2007/000204 WO2007082483A1 (en)	2006-01-20	2007-01-19	Medicament for treatment of tumor and the use thereof

Publications (3)

Publication Number	Publication Date
EP1985302A1 EP1985302A1 (de)	2008-10-29
EP1985302A4 true EP1985302A4 (de)	2013-01-02
EP1985302B1 EP1985302B1 (de)	2018-01-03

Family

ID=38287273

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP07702136.8A Active EP1985302B1 (de)	2006-01-20	2007-01-19	Arzneimittel zur tumortherapie und seine verwendung

Country Status (8)

Country	Link
US (2)	US20100285103A1 (de)
EP (1)	EP1985302B1 (de)
JP (2)	JP5687823B2 (de)
CN (3)	CN100475270C (de)
AU (1)	AU2007207268B2 (de)
CA (1)	CA2637698C (de)
NO (1)	NO20083287L (de)
WO (1)	WO2007082483A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104961831B (zh)	2007-09-05	2020-06-23	江苏先声药业有限公司	一种修饰的重组人内皮抑素及其应用
CN101396347B (zh) *	2007-09-27	2011-12-14	江苏先声药物研究有限公司	一种重组人血管内皮抑制素缓释微球的制备方法
CN101265298B (zh) *	2008-04-30	2011-11-09	中国药科大学	含有非天然氨基酸的内皮抑素突变体及其衍生物
CN101642559B (zh) *	2008-06-30	2012-08-01	江苏先声药物研究有限公司	含微粉化人血管内皮抑制素的药物组合物
US8507441B2 (en)	2009-10-22	2013-08-13	University of Pittsburgh—Of the Commonwealth Systems of Higher Education	Use of endostatin peptides for the treatment of fibrosis
WO2011123027A1 (en) *	2010-04-01	2011-10-06	Haraldsson Boerje	Improved treatment of renal cell carcinoma
CN101890155B (zh) *	2010-05-25	2012-07-25	江苏先声药物研究有限公司	一种药物组合物及其应用
CN102698270B (zh) *	2011-03-28	2016-02-03	清华大学	一种增强靶细胞摄取治疗剂的方法和药物组合物
JP6336389B2 (ja) *	2011-09-09	2018-06-06	チンファユニヴァーシティＴｓｉｎｇｈｕａＵｎｉｖｅｒｓｉｔｙ	Ａｔｐ結合部位に変異を有するエンドスタチン変異体
CN104926933B (zh) *	2014-03-19	2018-09-07	北京仁和天通生物科技有限公司	Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
CN104031261B (zh) *	2014-06-20	2017-10-27	电子科技大学	温敏性共聚物及其水凝胶体系
CN104174015A (zh) *	2014-08-22	2014-12-03	广州安辰医药科技有限公司	疫苗组合物及其在肿瘤治疗中的用途
CN104515768B (zh) *	2014-08-29	2017-01-25	湖南新大陆生物技术有限公司	一种肿瘤特异性生长因子检测试剂盒
CN104771603B (zh) *	2015-04-17	2018-05-18	张坤镛	一种改善唾液酸异常的中药口服药及制备方法
CN106924754B (zh) *	2015-12-30	2021-11-09	北京大学	聚氨基酸偶联物
CN105646701B (zh) *	2016-03-29	2019-03-05	徐根兴	不同氨基酸结构的重组人内皮抑素蛋白及其制备方法和应用
CN107865824B (zh) *	2016-09-28	2020-04-03	山东先声生物制药有限公司	一种稳定的重组人血管内皮抑制素皮下注射组合物
CA3043380A1 (en) *	2016-11-10	2018-05-17	Beijing Protgen Ltd.	Pegylated endostatin analogue and application thereof
WO2019024814A1 (zh) *	2017-07-30	2019-02-07	清华大学	抑制dna依赖蛋白激酶催化亚基的药物
CN109503700A (zh) *	2017-09-14	2019-03-22	南京安吉生物科技有限公司	马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN110870869A (zh) *	2018-08-31	2020-03-10	成都夸常奥普医疗科技有限公司	包含糖类营养素和常规无效化合物的药物组合物及其应用
CN117460533A (zh) *	2021-01-26	2024-01-26	清华大学	血管内皮抑制素在治疗和预防冠状病毒相关疾病中的应用
CN113350576A (zh) *	2021-05-21	2021-09-07	上海大学	快慢交联互补的双网络自愈合可注射水凝胶及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001087925A2 (en) *	2000-05-16	2001-11-22	Bolder Biotechnology, Inc.	Methods for refolding proteins containing free cysteine residues
WO2004020469A2 (en) *	2002-08-28	2004-03-11	Novartis Ag	Ocular gene therapy
US20040110671A1 (en) *	2002-12-05	2004-06-10	Yongzhang Luo	N-terminal modified recombinant human endostatin and its production

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4911929A (en)	1986-08-29	1990-03-27	The United States Of America As Represented By The Secretary Of The Navy	Blood substitute comprising liposome-encapsulated hemoglobin
WO1990015628A1 (en) *	1989-06-14	1990-12-27	Cetus Corporation	Polymer/antibiotic conjugate
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
TW517067B (en)	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
ATE245444T1 (de)	1998-02-09	2003-08-15	Enzon Pharmaceuticals Inc	Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
US6689762B1 (en)	1998-02-09	2004-02-10	Enzon Pharmaceuticals, Inc.	Composition and methods for treatment of HIV infection
TR200101086T2 (tr) *	1998-10-16	2001-08-21	Biogen, Inc.	Interferon beta-1A'nın polimer birleşikleri ve kullanımları.
EP1264840B1 (de)	1999-05-17	2009-09-23	ConjuChem Biotechnologies Inc.	Lang wirkende Peptidinhibitoren der Virusfusion mit Körperzellen bei viralen Infektionen
JP2003508501A (ja)	1999-09-07	2003-03-04	コンジュケム，インコーポレーテッド	生物学的結合のための肺送達
JP2004515232A (ja) *	2000-11-28	2004-05-27	フエニツクス・フアーマコロジクス・インコーポレーテツド	修飾されたアルギニンデイミナーゼ
EP1401480B1 (de) *	2001-02-22	2012-11-28	Novartis AG	Für endostatin kodierende virale vektoren zur behandlung von okularer neovaskularisation
WO2003066085A1 (en) *	2002-02-07	2003-08-14	Delta Biotechnology Limited	Albumin-fused anti-angiogenesis peptides
RU2294938C2 (ru) *	2002-07-24	2007-03-10	Ф.Хоффманн-Ля Рош Аг	Пэгилированный полипептид т1249
CN1997666A (zh)	2003-02-26	2007-07-11	印特缪恩股份有限公司	聚乙二醇修饰的干扰素组合物及其使用方法
US7524811B2 (en) *	2003-08-29	2009-04-28	Children's Medical Center Corporation	Anti-angiogenic peptides from the N-terminus of endostatin
AU2004269399A1 (en) *	2003-08-29	2005-03-10	Children's Medical Center Corporation	Anti-angiogenic peptides from the N-terminus of endostatin
EP1682582B1 (de)	2003-11-13	2011-08-31	Hanmi Holdings Co., Ltd	Verfahren zur massenproduktion der konstanten region von immunglobulin
EP1699821B1 (de)	2003-12-31	2012-06-20	Merck Patent GmbH	Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MIT VERBESSERTER PHARMAKOKINETIK
CN100355784C (zh)	2004-02-12	2007-12-19	江苏恒瑞医药股份有限公司	聚乙二醇修饰α－干扰素1b的制备方法
JP2005245269A (ja)	2004-03-03	2005-09-15	Nipro Corp	血清アルブミン多量体を含む遺伝子組換え型蛋白質
WO2005111072A2 (en)	2004-04-29	2005-11-24	The Trustees Of Columbia University In The City Of New York	Notch-based fusion proteins and uses thereof
CN1311867C (zh)	2004-09-27	2007-04-25	侯新朴	一种用于鼻腔给药的神经生长因子制剂
CN1891717A (zh) *	2005-07-08	2007-01-10	南京大学	内皮抑素的化学修饰方法及其应用

2006
- 2006-01-20 CN CNB2006100112479A patent/CN100475270C/zh not_active Expired - Lifetime
2007
- 2007-01-19 CA CA2637698A patent/CA2637698C/en active Active
- 2007-01-19 JP JP2008550619A patent/JP5687823B2/ja not_active Expired - Fee Related
- 2007-01-19 CN CN201410160386.2A patent/CN104043107B/zh active Active
- 2007-01-19 US US12/161,477 patent/US20100285103A1/en not_active Abandoned
- 2007-01-19 AU AU2007207268A patent/AU2007207268B2/en not_active Ceased
- 2007-01-19 CN CN200780010122.7A patent/CN101405019B/zh active Active
- 2007-01-19 EP EP07702136.8A patent/EP1985302B1/de active Active
- 2007-01-19 WO PCT/CN2007/000204 patent/WO2007082483A1/zh not_active Ceased
2008
- 2008-07-24 NO NO20083287A patent/NO20083287L/no not_active Application Discontinuation
2013
- 2013-02-26 JP JP2013036487A patent/JP2013163674A/ja active Pending
2018
- 2018-07-02 US US16/025,315 patent/US20180360922A1/en not_active Abandoned

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001087925A2 (en) *	2000-05-16	2001-11-22	Bolder Biotechnology, Inc.	Methods for refolding proteins containing free cysteine residues
WO2004020469A2 (en) *	2002-08-28	2004-03-11	Novartis Ag	Ocular gene therapy
US20040110671A1 (en) *	2002-12-05	2004-06-10	Yongzhang Luo	N-terminal modified recombinant human endostatin and its production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ROBERTS M J ET AL: "Chemistry for peptide and protein PEGylation", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 459 - 476, XP002293146, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(02)00022-4 *
See also references of WO2007082483A1 *
VERONESE F M: "Peptide and protein PEGylation - a review of problems and solutions", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(00)00193-9 *

Also Published As

Publication number	Publication date
CN101405019A (zh)	2009-04-08
JP2013163674A (ja)	2013-08-22
CN104043107A (zh)	2014-09-17
WO2007082483A1 (en)	2007-07-26
AU2007207268A1 (en)	2007-07-26
CA2637698C (en)	2016-09-20
JP5687823B2 (ja)	2015-03-25
US20180360922A1 (en)	2018-12-20
EP1985302B1 (de)	2018-01-03
JP2009523743A (ja)	2009-06-25
EP1985302A1 (de)	2008-10-29
CN100475270C (zh)	2009-04-08
NO20083287L (no)	2008-10-20
WO2007082483B1 (en)	2007-09-07
CA2637698A1 (en)	2007-07-26
CN101405019B (zh)	2014-06-04
AU2007207268B2 (en)	2011-08-18
CN101002946A (zh)	2007-07-25
US20100285103A1 (en)	2010-11-11
CN104043107B (zh)	2016-09-07

Publication	Publication Date	Title
EP1985302A4 (de)	2013-01-02	Arzneimittel zur tumortherapie und seine verwendung
EP1994181A4 (de)	2010-05-19	Identifizierung und verwendung von novopeptiden zur behandlung von krebs
FR25C1015I1 (fr)	2025-06-20	Traitement combiné de tumeurs exprimant la cd38
EP2322221A4 (de)	2013-02-27	Pharmazeutische zusammensetzung zur behandlung und prävention von krebs
EP2486134A4 (de)	2013-02-13	Verwendung eines toll-like-rezeptors und seines agonisten zur krebsbehandlung
EP2209371A4 (de)	2011-11-02	Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
EP2532680A4 (de)	2013-11-27	Medizinische zusammensetzung zur behandlung oder prävention von krebs
EP2651407A4 (de)	2014-06-04	3-methansulfonylpropionitril zur behandlung von entzündungen und schmerzen
EP2059210A4 (de)	2013-01-09	Therapeutische vorrichtungen zur behandlung verschiedener frauenleiden
FR2925339B1 (fr)	2010-03-05	Medicament pour le traitement du cancer du pancreas
EP2178455A4 (de)	2011-06-22	Vorrichtung zur behandlung von lebendem gewebe
EP2099448A4 (de)	2011-04-06	Pharmazeutische zusammensetzung zur behandlung und prävention von restenose
EP2349321A4 (de)	2012-12-19	Annexin und seine verwendung zur behandlung von entzündungserkrankungen
EP2154971A4 (de)	2010-05-19	Synergistische pharmazeutische kombination für die behandlung von krebs
EP2034841A4 (de)	2012-06-20	Verfahren und zusammensetzung für die behandlung von biofilmen
EP2194917A4 (de)	2012-01-04	Vorrichtungen und verfahren zur behandlung von adipositas
EP2068865A4 (de)	2011-08-10	Verfahren und zusammensetzungen für therapiebehandlung
EP2376091A4 (de)	2012-08-01	Neue targets zur behandlung von hypercholesterinmie
EP2049151A4 (de)	2010-03-24	Verfahren und zusammensetzungen zur behandlung von krebs
FR2929946B1 (fr)	2010-05-28	Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
EP2207892A4 (de)	2010-12-08	Verfahren zur selektion aktiver agentien für die krebsbehandlung
EP2361317A4 (de)	2014-01-01	Verwendung von eif3m zur diagnose und behandlung von krebs
EP2328604A4 (de)	2012-03-14	Verwendung von wnt5-a peptidderivaten zur behandlung von melanom und magenkarzinom
FR2907011B1 (fr)	2010-05-14	Utilisation de la citrulline pour le traitement des etats de denutrition
EP2331130A4 (de)	2012-11-07	Ige-antikörper zur behandlung von krebs

Legal Events

Date	Code	Title	Description
2008-09-26	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2008-10-29	17P	Request for examination filed	Effective date: 20080819
2008-10-29	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2008-10-29	AX	Request for extension of the european patent	Extension state: AL BA HR MK RS
2009-05-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1122498 Country of ref document: HK
2013-01-02	A4	Supplementary search report drawn up and despatched	Effective date: 20121129
2013-01-02	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/17 20060101AFI20121123BHEP Ipc: A61P 35/00 20060101ALI20121123BHEP Ipc: A61K 47/48 20060101ALI20121123BHEP Ipc: C07K 14/435 20060101ALI20121123BHEP
2016-01-06	17Q	First examination report despatched	Effective date: 20151208
2017-06-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602007053608 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0038170000 Ipc: A61K0047600000
2017-06-23	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2017-07-04	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2017-07-26	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/40 20060101ALI20170619BHEP Ipc: C07K 14/78 20060101ALI20170619BHEP Ipc: A61K 47/60 20170101AFI20170619BHEP Ipc: A61K 38/38 20060101ALI20170619BHEP Ipc: A61P 35/00 20060101ALI20170619BHEP Ipc: A61K 38/36 20060101ALI20170619BHEP
2017-08-02	INTG	Intention to grant announced	Effective date: 20170703
2017-10-31	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2017-11-24	GRAR	Information related to intention to grant a patent recorded	Free format text: ORIGINAL CODE: EPIDOSNIGR71
2017-11-24	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2017-12-01	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2017-12-06	INTC	Intention to grant announced (deleted)
2017-12-27	INTG	Intention to grant announced	Effective date: 20171123
2018-01-03	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2018-01-03	AX	Request for extension of the european patent	Extension state: AL BA HR MK RS
2018-01-03	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2018-01-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 959639 Country of ref document: AT Kind code of ref document: T Effective date: 20180115
2018-01-24	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2018-02-15	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602007053608 Country of ref document: DE
2018-02-28	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12
2018-05-09	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20180103
2018-05-25	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2018-06-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 959639 Country of ref document: AT Kind code of ref document: T Effective date: 20180103
2018-06-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: GR Ref document number: 1122498 Country of ref document: HK
2018-06-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103
2018-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103
2018-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180403 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180503 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180404
2018-10-05	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602007053608 Country of ref document: DE
2018-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103
2018-10-31	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2018-11-08	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20180131
2018-11-09	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2018-11-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2018-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180131 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103
2018-12-12	26N	No opposition filed	Effective date: 20181005
2019-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180119
2019-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103
2020-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20070119 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180103
2022-04-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20220215 Year of fee payment: 16 Ref country code: DE Payment date: 20220217 Year of fee payment: 16 Ref country code: CH Payment date: 20220221 Year of fee payment: 16
2022-06-01	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MC Payment date: 20220221 Year of fee payment: 16 Ref country code: LU Payment date: 20220217 Year of fee payment: 16 Ref country code: FR Payment date: 20220215 Year of fee payment: 16
2023-08-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602007053608 Country of ref document: DE
2023-08-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2023-09-27	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20230119
2023-09-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230119
2023-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230131 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230119 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230801 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230131
2023-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230131
2024-06-13	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230131
2024-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230131